Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
about
Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusionCytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortalityTherapeutic options for peritoneal metastasis arising from colorectal cancerOxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trialBenchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapyChallenges in the multidisciplinary management of stage IV colon and rectal cancer.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of recurrent/relapsed ovarian granulosa cell tumor: a single-center experience.Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view.A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma.Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
P2860
Q26768302-96BCBC65-54E2-4E1B-9AC6-D1EEC035108EQ26768309-BB312878-DB3F-4EEB-A8FC-7AE2461907EAQ28067123-D72D1B1D-3428-42CE-90A2-E821B068EEB6Q34491336-CC4B515B-659E-4CCF-96E9-908CC9EF6259Q34580450-6028448E-488F-40C4-A213-5708358FE433Q35005019-F88110F4-614A-468F-B161-51F1550832E3Q38246361-6D2C813E-D1A7-4DAD-9289-75A801D172CBQ41757594-7287C763-E2F7-4955-B158-E7A502FAE54DQ44242212-A9116EC2-E7A5-4103-BDB2-F5129956DF48Q47821560-0BB6E8CB-1E8D-40B1-BA45-5B004296FD6FQ49073965-68B64309-B401-4898-A577-1E4C491381C0
P2860
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Treatment-related morbidity an ...... osis: a matched-pair analysis.
@en
Treatment-related morbidity an ...... osis: a matched-pair analysis.
@nl
type
label
Treatment-related morbidity an ...... osis: a matched-pair analysis.
@en
Treatment-related morbidity an ...... osis: a matched-pair analysis.
@nl
prefLabel
Treatment-related morbidity an ...... osis: a matched-pair analysis.
@en
Treatment-related morbidity an ...... osis: a matched-pair analysis.
@nl
P2093
P2860
P356
P1476
Treatment-related morbidity an ...... osis: a matched-pair analysis.
@en
P2093
Gabriel Glockzin
Hans J Schlitt
Philipp von Breitenbuch
Pompiliu Piso
P2860
P304
P356
10.1002/JSO.23228
P577
2012-07-25T00:00:00Z